Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days

NCT01446042 is registered in ClinicalTrials.gov with Acerus Pharmaceuticals Corporation as lead sponsor.

NCT NCT01446042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01446042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Lead sponsor
Acerus Pharmaceuticals Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
March 31, 2013
Enrollment
306 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

male hypogonadism